
TY  - JOUR
AU  - Cacabelos, Ramón
TI  - Pharmacogenomics of Central Nervous System (CNS) Drugs
JO  - Drug Development Research
JA  - Drug Dev. Res.
VL  - 73
IS  - 8
SN  - 0272-4391
UR  - https://doi.org/10.1002/ddr.21039
DO  - doi:10.1002/ddr.21039
SP  - 461
EP  - 476
KW  - CNS disorders
KW  - Alzheimer's disease
KW  - pharmacogenomics
KW  - CYP2D6
KW  - CYP2C9
KW  - CYP2C19
KW  - CYP3A4/5
KW  - APOE
KW  - transporters
KW  - psychotropic drugs
PY  - 2012
AB  - Abstract Preclinical Research Central nervous system (CNS) disorders represent a major problem of health in developed countries, with important consequences in disability and health economics. Recent findings in CNS genomics and pharmacogenomics suggest that the introduction of pharmacogenomic procedures in clinical practice may help to optimize therapeutics (efficacy and safety issues). The genes involved in the pharmacogenomics of CNS drugs fall into five categories: (i) genes associated with CNS pathogenesis; (ii) genes associated with the mechanism of action of drugs; (iii) genes associated with drug metabolism; (iv) genes associated with drug transporters; and (v) pleiotropic genes involved in multifaceted cascades and metabolic reactions. Pharmacogenomics accounts for 30?90% variability in pharmacokinetics and pharmacodynamics. Only 20?30% of the Caucasian population processes normally approximately 60% of the current drugs that are metabolized via CYP2D6, CYP2C9, and CYP2C19. Clinical pharmacogenomics may contribute to personalizing pharmacological treatment, predicting patient/drug-dose selection, minimizing drug interactions, increasing drug efficacy, and reducing unnecessary costs.
ER  - 

TY  - JOUR
AU  - Thébault, Sandrine
AU  - Deniel, Nicolas
AU  - Galland, Alexandra
AU  - Lecleire, Stéphane
AU  - Charlionet, Roland
AU  - Coëffier, Moïse
AU  - Tron, François
AU  - Vaudry, David
AU  - Déchelotte, Pierre
TI  - Human duodenal proteome modulations by glutamine and antioxidants
JO  - PROTEOMICS – Clinical Applications
JA  - Prot. Clin. Appl.
VL  - 4
IS  - 3
SN  - 1862-8346
UR  - https://doi.org/10.1002/prca.200800175
DO  - doi:10.1002/prca.200800175
SP  - 325
EP  - 336
KW  - Antioxidant
KW  - Duodenum
KW  - Glutamine
KW  - Nutrition
PY  - 2010
AB  - Abstract Purpose: Glutamine (Gln) has protective, anti-inflammatory effects in animal models and humans. Antioxidant nutrients may exert synergistic effects on intestinal functions. Therefore, these combined nutrients may have a therapeutic potential during intestinal inflammation. This study was designed to investigate in humans the effects of a supplement composed of Gln and high-dosed antioxidant micronutrients compared to isomolar Gln only, on duodenal proteome. Experimental design: Enteral perfusion of Gln (0.8?mmol?.?kg?1.?h?1) or supplement was performed in two groups of six healthy volunteers during 5?h before taking endoscopic duodenal biopsies. Protein expression was analyzed by 2-DE and the relevant proteins identified by MS/MS. Results: About 1500 protein spots were revealed in both supplement and Gln conditions. Comparative proteomics analysis indicated that 11 proteins were differentially and significantly (p≤0.05) expressed in response to the supplement. These proteins were essentially implicated in metabolism pathways, e.g. fatty acid binding protein-1 and 40S ribosomal protein SA expressions were downregulated while manganese superoxide dismutase and retinal dehydrogenase-1 expressions were upregulated. Conclusions and clinical relevance: This study provides new information on human duodenal proteome and its nutritional modulation, and supports further clinical investigations designed to evaluate the effects of Gln plus antioxidants during intestinal inflammation and cancer.
ER  - 

TY  - JOUR
TI  - Abstract
JO  - Diseases of the Esophagus
JA  - DISEASES OF THE ESOPHAGUS
VL  - 29
IS  - S1
SN  - 1120-8694
UR  - https://doi.org/10.1111/dote.12528
DO  - doi:10.1111/dote.12528
SP  - 3A
EP  - 162A
PY  - 2016
ER  - 

TY  - JOUR
TI  - E-Poster Presentations (Oral) | APDW 2019
JO  - Journal of Gastroenterology and Hepatology
JA  - Journal of Gastroenterology and Hepatology
VL  - 34
IS  - S3
SN  - 0815-9319
UR  - https://doi.org/10.1111/jgh.14879
DO  - doi:10.1111/jgh.14879
SP  - 72
EP  - 582
PY  - 2019
ER  - 

TY  - JOUR
TI  - Poster Session 2: Experimental Hepatocarcinogenesis
JO  - Hepatology
JA  - Hepatology
VL  - 60
IS  - S1
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.27515
DO  - doi:10.1002/hep.27515
SP  - 634A
EP  - 658A
PY  - 2014
ER  - 

TY  - JOUR
TI  - Abstracts—Posters
JO  - Alcoholism: Clinical and Experimental Research
JA  - Alcohol Clin Exp Re
VL  - 43
IS  - S1
SN  - 0145-6008
UR  - https://doi.org/10.1111/acer.14059
DO  - doi:10.1111/acer.14059
SP  - 27A
EP  - 258A
PY  - 2019
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Hepatology
JA  - Hepatology
VL  - 54
IS  - S1
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.24666
DO  - doi:10.1002/hep.24666
SP  - 360A
EP  - 1455A
PY  - 2011
ER  - 

TY  - JOUR
TI  - Thematic Poster Sessions – Monday
JO  - Allergy
VL  - 66
IS  - s94
SN  - 0105-4538
UR  - https://doi.org/10.1111/j.1398-9995.2011.02607.x
DO  - doi:10.1111/j.1398-9995.2011.02607.x
SP  - 320
EP  - 481
PY  - 2011
ER  - 

TY  - JOUR
TI  - POSTER PRESENTATION: BILIARY
JO  - HPB
VL  - 14
IS  - s2
SN  - 1365-182X
UR  - https://doi.org/10.1111/j.1477-2574.2012.00512.x
DO  - doi:10.1111/j.1477-2574.2012.00512.x
SP  - 288
EP  - 699
PY  - 2012
ER  - 

TY  - JOUR
TI  - Posters (Abstracts 301–2389)
JO  - Hepatology
JA  - Hepatology
VL  - 68
IS  - S1
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.30257
DO  - doi:10.1002/hep.30257
SP  - 184
EP  - 1353
PY  - 2018
ER  - 

TY  - JOUR
TI  - Poster Panel [Liver]
JO  - HPB
JA  - HPB
VL  - 16
IS  - s2
SN  - 1365-182X
UR  - https://doi.org/10.1111/hpb.12234
DO  - doi:10.1111/hpb.12234
SP  - 406
EP  - 549
PY  - 2014
ER  - 

TY  - JOUR
TI  - Research Communications of the 26th ECVIM-CA Congress
JO  - Journal of Veterinary Internal Medicine
JA  - J Vet Intern Med
VL  - 31
IS  - 1
SN  - 0891-6640
UR  - https://doi.org/10.1111/jvim.14600
DO  - doi:10.1111/jvim.14600
SP  - 186
EP  - 270
PY  - 2017
ER  - 

TY  - JOUR
TI  - Abstracts—Posters
JO  - Alcoholism: Clinical and Experimental Research
VL  - 35
IS  - s1
SN  - 0145-6008
UR  - https://doi.org/10.1111/j.1530-0277.2011.01497.x
DO  - doi:10.1111/j.1530-0277.2011.01497.x
SP  - 11A
EP  - 262A
PY  - 2011
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - American Journal of Transplantation
VL  - 18
IS  - S4
SN  - 1600-6135
UR  - https://doi.org/10.1111/ajt.14918
DO  - doi:10.1111/ajt.14918
SP  - 479
EP  - 991
PY  - 2018
ER  - 

TY  - JOUR
TI  - Orals
JO  - Transplant International
JA  - Transpl Int
VL  - 26
IS  - s2
SN  - 0934-0874
UR  - https://doi.org/10.1111/tri.12210
DO  - doi:10.1111/tri.12210
SP  - 1
EP  - 184
PY  - 2013
ER  - 

TY  - JOUR
TI  - Posters (Abstracts 289–2348)
JO  - Hepatology
JA  - Hepatology
VL  - 70
IS  - S1
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.30941
DO  - doi:10.1002/hep.30941
SP  - 188
EP  - 1382
PY  - 2019
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - Journal of Gastroenterology and Hepatology
JA  - J Gastroenterol Hepatol
VL  - 28
IS  - S3
SN  - 0815-9319
UR  - https://doi.org/10.1111/jgh.12363_2
DO  - doi:10.1111/jgh.12363_2
SP  - 23
EP  - 693
PY  - 2013
ER  - 

TY  - JOUR
TI  - Posters
JO  - Basic & Clinical Pharmacology & Toxicology
VL  - 107
IS  - s1
SN  - 1742-7835
UR  - https://doi.org/10.1111/j.1742-7843.2010.00600.x
DO  - doi:10.1111/j.1742-7843.2010.00600.x
SP  - 162
EP  - 692
PY  - 2010
ER  - 

C7  - pp. 23-133
TI  - Cell surface and secreted proteins
SN  - 9781118849859
UR  - https://doi.org/10.1002/9781118849842.ch3
DO  - doi:10.1002/9781118849842.ch3
SP  - 23-133
KW  - adhesion molecules
KW  - ATP-binding cassette
KW  - cell surface
KW  - cytokines
KW  - GPCRs
KW  - host defence molecules
KW  - NHRS
KW  - secreted proteins
KW  - transporters
PY  - 2010
AB  - Summary This chapter includes HGNC entries for proteins that are expressed on the cell surface, namely receptors for different ligand classes, transporters and ion channels. Targets for existing drugs are strongly over-represented in this group; for example, approximately 40% of current medicines affect G-protein-coupled receptors (GPCRs), and hundreds of these molecules are listed with annotations that indicate pharmaceutical potential. The chapter also discusses targets that involve protein-protein or protein-carbohydrate interactions. These are cytokines and their receptors, adhesion molecules and host defence molecules; the allocation of entries in these three sections is less clear-cut than with the GPCRs. The last group of entries that is discussed is the transporters and channels. The ATP-binding cassette and solute carrier families are not only primary therapeutic targets but also contain proteins that contribute to drug resistance.
ER  - 

TY  - JOUR
TI  - Oral Presentations
JO  - Neurogastroenterology & Motility
JA  - Neurogastroenterol. Motil.
VL  - 28
IS  - S1
SN  - 9781118849859
UR  - https://doi.org/10.1111/nmo.12881
DO  - doi:10.1111/nmo.12881
SP  - 5
EP  - 108
PY  - 2016
ER  - 
